Table 1.
Baseline characteristics of the study population
| Mean age, years (SD) | 81.3 (9.5) |
| Sex (%) | |
| Female | 36 (69.2) |
| Male | 16 (30.8) |
| Eye (%) | |
| Right | 28 (53.8) |
| Left | 24 (46.2) |
| Anti-VEGF treatment prior to switch (%) | |
| Aflibercept | 42 (80.8) |
| Ranibizumab | 9 (19.3) |
| Bevacizumab | 1 (1.9) |
| Median duration of prior anti-VEGF therapy, months (range) | 27.5 (2–69) |
| Median number of injections of prior anti-VEGF therapy, (range) | 20 (3–64) |
| Reason for change of therapy to IVBr, n (%) | |
| Persistent recalcitrant macular fluid | 23 (44.2) |
| Extension of treatment interval | 18 (34.6) |
| Both | 11 (21.2) |
| Previous anti-VEGF treatment interval prior to brolucizumab, weeks (mean (SD) | 6.1 (3.1) |
| Number of intravitreal injections with prior anti-VEGF agent (%) | |
| 1–5 | 9 (17.3) |
| 6–10 | 4 (7.7) |
| >10 | 39 (75.0) |
| Baseline macular fluid status (%) | |
| Subretinal fluid (SRF) only | 18 (34.6) |
| Intraretinal fluid (IRF) only | 14 (26.9) |
| Concurrent SRF and IRF | 6 (11.5) |
| Macular hemorrhage | 1 (1.9) |
| No fluid | 13 (25.0) |
Abbreviations: IVBr, intravitreal brolucizumab; SRF, subretinal fluid; IRF, intraretinal fluid.